Evidence-Based Treatment for ALK and ROS1 Rearrangement–Positive NSCLC
Source: Focus on Advanced NSCLC: Expert Insights and Strategies for Refining Patient Care

Clinical Focus

In this interactive, CME/CE-certified module, Alice Shaw, MD, PhD, provides her perspective on optimizing treatment strategies for advanced-stage ALK and ROS1 rearrangement–positive NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guideline recommendations and available clinical data to individualize the care of newly diagnosed patients with advanced-stage NSCLC with ALK or ROS1 translocations
  • Incorporate recently approved treatment options into the management of patients with advanced-stage NSCLC with ALK or ROS1 translocations who have progressed on previous therapy

Topics Covered Include:

  • ALK- or ROS1-Positive Non-Small-Cell Lung Cancer
  • Selecting Treatment for Newly Diagnosed Advanced ALK- Positive NSCLC
  • Selecting Treatment for Progressive ALK-Positive NSCLC
  • Selecting Treatment for Newly Diagnosed Advanced ROS1-Positive NSCLC
 

Faculty

  • Alice Shaw
    MD, PhD

Credit Information

  • Release Date:
    December 28, 2016
  • Expiration Date:
    December 27, 2017
  • Physicians:
    maximum of 0.75 AMA PRA Category 1 Credits
  • Registered Nurses:
    0.7 Nursing contact hours

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Alice Shaw, MD, PhD


Associate Professor of Medicine
Harvard Medical School
Director, Center for Thoracic Centers
Paula O'Keefe Endowed Chair in Thoracic Oncology
MGH Cancer Center/Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts

Alice Shaw, MD, PhD, has disclosed that she has received consulting fees from Ariad, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Genentech, Ignyta, Loxo Oncology, Novartis, Pfizer, Roche, and Taiho.
 

Staff

Timothy A. Quill, PhD


Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
 

Rachael M. Andrie, PhD


Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

Heather Stieglitz, PhD


Editorial Contributor

Heather Stieglitz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for academic and community-based medical oncologists, pulmonologists, pathologists, and oncology nurses, as well as other healthcare professionals who treat patients with lung cancer.


Goal

The goal of this activity is to provide educational activities and resources that will improve the competence and performance of healthcare providers to positively affect the health of patients with non-small-cell lung cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guideline recommendations and available clinical data to individualize the care of newly diagnosed patients with advanced-stage NSCLC with ALK or ROS1 translocations
  • Incorporate recently approved treatment options into the management of patients with advanced-stage NSCLC with ALK or ROS1 translocations who have progressed on previous therapy
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Credit Designation

This educational activity for 0.7 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

 

Commercial Support


This program is supported by educational grants from AbbVie, Celgene Corporation, Genentech, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 28, 2016, through December 27, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.